Vyndaqel

Vyndaqel (tafamidis meglumine) is an oral medication used to treat transthyretin amyloidosis. This rare disease affects protein buildup in tissues. Learn more about tafamidis meglumine uses and effects.

Vyndaqel (tafamidis meglumine) is prescribed to slow progression in transthyretin amyloidosis, a condition where abnormal proteins build up in organs and nerves. It helps stabilize the protein transthyretin to reduce misfolding and tissue damage. This medication is used for both hereditary and wild-type forms of the disease.

Vyndaqel works by binding to transthyretin, helping to keep the protein stable and preventing it from breaking down into harmful fragments. This may reduce symptoms such as nerve pain, muscle weakness, and heart-related issues over time. Patients may notice gradual improvements in mobility and daily functioning.

Store Vyndaqel at room temperature away from moisture and heat. Keep this medication in its original blister pack until ready to use. Always handle with dry hands and avoid splitting or crushing the capsules. If a dose is missed, take it as soon as remembered unless it’s nearly time for the next dose.

Vyndaqel may interact with medications that affect liver enzymes, such as certain antibiotics or antifungals. Combining it with alcohol or herbal supplements like St. John’s Wort could alter its effectiveness. Always inform your healthcare provider about all medications and supplements you are taking before starting Vyndaqel.